EMBOLIC COMPOSITIONS

• US 20180055516A1
• Filed: 08/25/2017
• Published: 03/01/2018
• Est. Priority Date: 08/26/2016
• Status: Active Grant

• Current Assignee: Microvention Incorporated (Terumo Corporation)
• Original Assignee: Microvention Incorporated (Terumo Corporation)
• Inventors: Baldwin, Aaron, Mehta, Ami, Lam, Jonathan
• Granted Patent: US 10,368,874 B2
• Time in Patent Office: Days
• CPC Class Codes: A61B 17/12181 formed by fluidized, gelatinous or cellular remodelable materials, e.g. embolic liquids, foams or extracellular matrices
• CPC Class Codes: A61B 17/12186 liquid materials adapted to be injected
• CPC Class Codes: A61B 2017/00938 hydrophobic
• CPC Class Codes: A61B 2017/00942 hydrophilic
• CPC Class Codes: A61B 2090/3933 Liquid markers
• CPC Class Codes: A61B 2090/3966 Radiopaque markers visible in an X-ray image
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61K 49/0438 Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
• CPC Class Codes: A61K 49/0442 Polymeric X-ray contrast-enhancing agent comprising a halogenated group
• CPC Class Codes: C08F 20/26 Esters containing oxygen in addition to the carboxy oxygen
• CPC Class Codes: C08L 33/14 of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen

Abstract

Described herein are compositions comprising, a polymer; a non-physiological solution; and a visualization agent; wherein the polymer is soluble in the non-physiological solution and insoluble at physiological conditions. Methods of preparing the compositions are disclosed as well as methods of using these compositions to treat vascular conditions.

Claims

1. A composition comprising:

a biocompatible polymer including an amine;

a solvent; and

a visualization agent;

wherein the biocompatible polymer is soluble in the solvent and insoluble at physiological conditions.

2. The composition of claim 1, wherein the visualization agent is integrated into or associated with into the biocompatible polymer.

3. The composition of claim 2, wherein the visualization agent is triiodophenol-lactide-glycolide (TIP).

4. The composition of claim 1, wherein the physiological conditions include contact with a physiological fluid including blood, urine, saliva, mucous, vaginal fluid, seminal fluid, cerebral spinal fluid, sweat, plasma, bile, stomach acid, intestinal fluids, or a combination thereof.

5. The composition of claim 4, wherein the physiological fluid has a pH of about 7.0.

6. The composition of claim 4, wherein the physiological fluid has a pH of between about 7.0 and about 7.8.

7. The composition of claim 1, wherein the solvent is a water miscible organic solvent.

8. The composition of claim 1, wherein the amine includes an amino group which is about 90% positively charged at a pH of 5 and about 10% positively charged at a pH of 7.

9. The composition of claim 1, wherein the biocompatible polymer includes hydroxyethylmethacrylate (HEMA), lactide, glycolide, polyvinyl pyridine (PVP), 1-vinylimidazole, aminoethyl methacrylate (AEMA), 4-vinylpyridine, alkylalkylacrylate, alkylacrylate, acrylate, styrene, polyvinyl alcohol (PVA), acrylamide, ethylene glycol, or combinations thereof.

10. The composition of claim 1, wherein the biocompatible polymer includes about 60% w/w HEMA and the visualization agent includes about 40% w/w TIP.

11. The composition of claim 1, wherein the biocompatible polymer includes about 15% w/w HEMA and the visualization agent includes about 85% w/w TIP.

12. The composition of claim 1, wherein the solvent is water or a co-solvent of water and dimethyl sulfoxide (DMSO).

20. A method of delivering a composition comprising:

injecting the composition of claim 1 through a delivery device into a location with the physiological condition.

13. A composition comprising:

a precipitating hydrophobic injectable liquid (PHIL) comprising a polymer having a viscosity of less than about 16 centistoke; and

a solvent;

wherein the PHIL is soluble in the solvent and insoluble at physiological conditions.

14. The composition of claim 13, wherein the polymer includes TIP and HEMA.

15. The composition of claim 13, wherein the solvent is DMSO.

16. The composition of claim 13, wherein the PHIL includes 25% w/w polymer and 75% w/w solvent.

17. The composition of claim 13, further comprising a radiopaque compound.

18. The composition of claim 17, wherein the radiopaque compound is an iodinated compound, a metal particle, barium sulfate, superparamagnetic iron oxide, gadolinium, tantalum, tungsten carbide, molybdenum, rhenium, or a combination thereof.

19. The composition of claim 13, wherein the PHIL is less than about 20% w/w polymer.